Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1681 to 1695 of 1773 results for patient safety

  1. Pegcetacoplan for treating geographic atrophy [ID4041]

    Discontinued Reference number: GID-TA11351

    Technology appraisal guidance
    Discontinued

  2. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Service user experience in adult mental health services (QS14)

    This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    31 July 2019
    View quality statements

    Sections for QS14

  4. Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

    Discontinued Reference number: GID-TA10105

    Technology appraisal guidance
    Discontinued

  5. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued Reference number: GID-TA10164

    Technology appraisal guidance
    Discontinued

  6. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

    Technology appraisal guidance
    Discontinued

  7. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued Reference number: GID-TAG507

    Technology appraisal guidance
    Discontinued

  8. Evidence on the safety and efficacy of intramedullary distraction for upper limb lengthening is inadequate in quantity and quality. But because this is a rare condition with limited alternative treatments, the procedure can be considered as long as special arrangements for clinical governance, consent, and audit or research are in place. Find out what special arrangements mean on the NICE interventional procedures guidance page. Further research, which could be registry data, should report details of patient  selection, device selection, technique used, procedural outcomes, long-term  outcomes including quality of life, the need for repeat interventions or surgery and complication rates.

    Recommendation ID IPG722/01 Question Evidence on the safety and efficacy of intramedullary distraction for upper limb lengthening is...

    Research recommendation
    Published
    11 May 2022

  9. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

    Technology appraisal guidance
    Discontinued

  10. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development Reference number: GID-TA10489 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

    Technology appraisal guidance
    Discontinued

  12. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

    Technology appraisal guidance
    Discontinued

  13. Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis (HTG501)

    Evidence-based recommendations on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in people with multiple sclerosis. This involves inserting an inflatable balloon into veins in the neck and chest in an attempt to widen them.

    HealthTech guidance
    Published
    30 January 2019
    View recommendations

    Sections for HTG501

  14. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued Reference number: GID-TA10277

    Technology appraisal guidance
    Discontinued

  15. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

    Technology appraisal guidance
    Discontinued